Areas
Health
Fields of use
Healthcare-Medical Science; antibacterial drug discovery
Current state of technology
Laboratory tested; preclinical
Intellectual property
Patent application: LU100918
Developed by
University of Ljubljana, Faculty of Pharmacy, University of Helsinki (UH) and Biological Research Center of the Hungarian Academy of Sciences, Szeged
Reference
821-15/2018
Contact
Knowledge Transfer Office UL
Gabriela Droga Mazovec
Tel: +386 70 538 284
E-pošta: gospodarstvo@uni-lj.si
Download PDF
Background
The increasing number of life-threatening infections due to resistant Gram-positive and Gram-negative pathogens is alarming. In the last 50 years, the number of multi-drug resistant (MDR) bacteria is rising and the number of drugs crossing the first testing phases is very limited.
Description of invention
We have discovered a new class of inhibitors of the ATPase domains of DNA gyrase and/or topoisomerase IV. The benzothiazole scaffold-based compounds, that can be used in the manufacture of drugs, are effective against both Gram-positive and Gram-negative pathogens in humans. Examples include pathogens of the “ESKAPE” group (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species).
Main advantages
Most inhibitors previously described showed activity only against Gram-positive strains and were not successful in clinical trials due to their high toxicity profile. Our compounds show promising possibilities for derivatization and are active against both Gram-positive and Gram-negative bacteria.